Can inhibition of cyclin B1 destruction in G1 of mitosis be exploited to promote cancer cell death?
Can inhibition of cyclin B1 destruction in G1 of mitosis be exploited to promote cancer cell death?
批准号:
2753329
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
背景;CDK活性的振荡从G1细胞周期开始就驱动细胞周期进程。事实上,从G1的最早阶段开始,CDK活性在细胞“决定”是否进入细胞周期(通过启动DNA复制)或退出休眠中起着核心作用。重要的是,CDKs只有在与细胞周期蛋白结合时才有活性。有许多细胞周期蛋白- cdk复合物,然而,只有细胞周期蛋白B1-CDK1活性是必不可少的。关键的是,CDK活性水平受到高度调节,以正确的速度驱动进程,从而有足够的时间准确地完成周期的每个阶段。为了促进这一过程,在健康细胞中,周期蛋白水平被严格降低。相反,细胞周期蛋白B1 (B1)在许多人类癌症中过度表达。此外,它的上调与预后不良、治疗耐药有关,并被认为是癌细胞与其微环境之间启动通信的信号。事实上,高表达的B1从G1开始就与CDK1结合,促进肿瘤组织的侵袭性增殖。我们已经发现了B1中的一个新的基序,该基序对于B1在卵母细胞减数分裂中过量存在的调控至关重要(ref)。在此之后,我们在有丝分裂中获得了令人兴奋的未发表数据,表明如果B1过表达,该相同的基序对于稳定B1水平G1很重要。值得注意的是,当我们抑制对该基序的访问时,过度表达B1的细胞死亡。目标;1。探讨有丝分裂G1期B1水平过高调控的分子机制。2. 在此基础上,提出候选蛋白,如果受到干扰,可以阻止这种机制的过量B1调节,迫使细胞死亡。新颖性和时效性;我们在有丝分裂中的数据是全新的,为我们提供了一个独特的机会,以确定我们可能触发细胞死亡的新机制。值得注意的是,这种B1调节机制仅在过表达B1的细胞中是必需的,这意味着任何未来的衍生治疗方案都可以区分不稳定细胞和健康细胞。这是及时的,因为临床医生正在寻找有效的治疗方法来保护健康细胞(限制一些替代治疗方法经常使人衰弱的脱靶效应)。实验方法;学生将在活的有丝分裂细胞中通过Bio-ID测定,以及在有或没有这个关键基序的表达B1的裂解细胞中通过IP实验,识别G1中新的周期蛋白B1基序的结合伙伴(实验1)。然后,他们将在体内测定中确认候选蛋白质,如bbic以确认接近性(实验室1并与VisiTech合作)和体外测定(通过生成蛋白质以表征生物化学相互作用;实验室2)。最后,我们将确定我们感兴趣的相互作用蛋白中的突变,这些突变会干扰B1的调节,导致细胞死亡。
英文摘要
Background; Oscillations in CDK activity drive cell-cycle progression from the outset of the cell cycle in G1. Indeed, from the earliest stages of G1, CDK activity plays a central role in a cells 'decision' to either commit to cell-cycle entry (by initiating DNA replication) or exit into quiescence. Importantly, CDKs are only active when bound to cyclins. There are many cyclin-CDK complexes, however, only cyclin B1-CDK1 activity is essential. Critically, CDK activity levels are highly regulated to drive progression at the correct speed, allowing sufficient time to complete each stage of the cycle accurately. To facilitate this cyclin levels are strictly attenuated in healthy cells.In contrast, cyclin B1 (B1) is overexpressed in numerous human cancers. Further, its upregulation is associated with poor prognosis, treatment resistance, and suggested to act as a signal that initiates communications between cancer cells and their microenvironment. Indeed, highly expressed B1 binds to CDK1 from the outset in G1, contributing to aggressive proliferation in neoplastic tissues. We have revealed a novel motif in B1 that is critical for its regulation where B1 exists in excess in oocyte meiosis (ref). Following this, we have exciting unpublished data in mitosis demonstrating that this same motif is important to stabilise B1 levels G1 if B1 is overexpressed. Significantly, where we inhibit access to this motif, cells overexpressing B1 die. Objectives;1. To identify the molecular mechanism by which excessive levels of B1 are regulated in G1 of mitosis. 2. Following this, to propose candidate proteins which if perturbed, prevent this mechanism of excess B1 regulation, forcing cell death.Novelty and Timeliness; Our data in mitosis are entirely novel and present us with a unique opportunity, to identify a new mechanism by which we may trigger cell death. Significantly, this mechanism of B1 regulation is only essential in cells overexpressing B1, meaning that any future derived treatment programme could differentiate between unstable and healthy cells. This is timely as clinicians search for effective treatments that preserve healthy cells (limiting the often debilitating off target effects of some alternative treatments). Experimental Approach; The student will identify binding partners of the novel cyclin B1 motif in G1 by Bio-ID assay in live mitotic cells, and by IP experiments with lysed cells over expressing B1 with and without this critical motif (lab 1). They will then confirm candidate proteins in in-vivo assays such as BiFc to confirm proximity (lab 1 and in collaboration with VisiTech) and in-vitro (by generating proteins to characterise interactions biochemically; lab 2). Finally, we will identify mutations in our interacting protein(s) of interest that perturbs the regulation excess B1, resulting in cell death.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
槐耳联合CDK4/6抑制剂调控Cyclin D1-CDK4/6-Rb通路在乳腺癌中的作用及机制研究
-
批准号:2026JJ82715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:廖妮
-
依托单位:
新型铜载体天然产物Chalkphomycin通过ATM酶-CHK2-Cyclin D1轴抗黑色素瘤作用机制研究
-
批准号:2025JJ80302
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:龚邦
-
依托单位:
青蒿琥酯调控Nrf2/HO-1-Cycin D1/CDK4-pRB信号轴诱导甲状腺相关眼病成纤维细胞衰老的机制研究
-
批准号:2025JJ60577
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:刘静远
-
依托单位:
Cyclin D1-Dicer正反馈回路调控胆管癌细胞基因组CpG位点从头甲基化的机制
-
批准号:LQ23C060003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:齐永强
-
依托单位:
靶向CDK7/cyclin H复合物的选择性小分子降解剂的设计合成与活性研究
-
批准号:22377013
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:林华
-
依托单位:
tRF-28-ZJ47D112Z4DZ通过Cyclin D1/CDK4抑制胃癌发生的机制及其早期诊断价值研究
-
批准号:82302611
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:俞秀冲
-
依托单位:
Anxa2调控Cyclin D1促进乳腺癌细胞他莫昔芬耐药及侵袭性增强的机制研究
-
批准号:82272640
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:王彤
-
依托单位:
低分子量Cyclin E1在骨肉瘤中表达的临床意义及其促进骨肉瘤恶性进展的作用与机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:尉然
-
依托单位:
LncRNA-CASC2/miR-155-5p/cyclin D1轴在妊娠期亚甲减绒毛外滋养细胞侵袭迁移中的作用及补肾安胎方的干预研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:张泰魏
-
依托单位:
黑色素瘤CCND1基因拷贝数变异及Cyclin D1蛋白异常表达的病理临床特征及潜在介导免疫耐药的机制研究
-
批准号:2022J011054
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:陈丽珠
-
依托单位: